NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DA-22-031 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research projects focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This FOA is part of the NIH Helping to End Addictions Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose. https://heal.nih.gov/research/medication-options
Funding Opportunity RFA-DA-22-032 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research projects focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This FOA is part of the NIH Helping to End Addictions Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose. https://heal.nih.gov/research/medication-options
Notice NOT-HL-21-017 from the NIH Guide for Grants and Contracts
Request for Information (RFI): Transporters of Nutrients, Dietary Components, Metabolites, and Drugs
Notice NOT-OD-21-148 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-21-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U24 cooperative agreement applications for a Knowledge Management Center (KMC) to support grantees engaged in identifying and characterizing microbial metabolites for building a knowledgebase. A companion FOA [PAR-21-253, Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)] invites applications for identifying and characterizing microbial metabolites that will be used by this KMC to create a knowledgebase on microbial metabolites that is accessible to the research community.
Funding Opportunity PAR-21-253 from the NIH Guide for Grants and Contracts. The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterizemicrobial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acquired through this initiative will be used to create aknowledgebase of microbial metabolites and associated functions that will be provided to the research community. Development of the database and knowledge portal for these awards will be supported under a separate initiative: RFA-DK-21-014, namely Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center U24 Resource-Related Research Projects Cooperative Agreements.
Funding Opportunity PAR-21-246 from the NIH Guide for Grants and Contracts. The goals of this program are to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity, and build a network of researchers both within and across LMICs to address this critical burden. This initiative is expected to stimulate new research on the interplay between HIV and development of NCDs in persons living with HIV (PLWH), including exploratory studies to uncover the extent to which HIV infection influences the etiopathogenesis of the NCDs; and to identify and develop appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for PLWH with the comorbid conditions. Applicants should develop their studies in keeping with the NIH HIV/AIDS Research Priorities ( https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html; https://www.oar.nih.gov/hiv-policy-and-research/research-priorities). Research teams should contain an appropriate mix of expertise to accomplish the proposed studies, including partnerships between HIV and NCD researchers who can initiate new ideas and determine feasibility of novel approaches to understand and reduce the long-term suffering from the comorbid disorders. Applicants will also be asked to address the needs of collaborating LMIC institutions to develop capacity for carrying out research in this field. U.S. and LMIC investigators are eligible to apply for collaborative projects to be done at LMIC sites; however, a U.S. investigator must apply together with an LMIC investigator. LMICs are defined by the World Bank classification system according to Gross National Income (GNI) per capita as low-income, lower-middle-income, and upper-middle-income (http://data.worldbank.org/about/country-classifications/country-and-lending-groups).
Funding Opportunity RFA-DA-22-020 from the NIH Guide for Grants and Contracts. This FOA solicits applications to develop the customized curriculum and to implement the education programs/short courses in biomedical entrepreneurship, innovation and biomedical product development specifically targeting scientists working in the field of drug addiction research. The institution proposing the course must be an institution that has an established and well-recognized entrepreneurship teaching program with the demonstrated ability and passion to adapt/develop and deliver the integrated curriculum for the academic life scientists.
Notice NOT-AA-21-037 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-031 from the NIH Guide for Grants and Contracts
Notice NOT-HL-21-019 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-21-021 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) invites research grant proposals for transdisciplinary studies that will enhance our knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation and increased cancer risk. Through this Funding Opportunity Announcement (FOA), the Metabolic Dysregulation and Cancer Risk Program will focus on metabolic dysregulation as the key process linking obesity with cancer risk. For the purpose of this FOA, metabolic dysregulation is defined as alterations in glucose utilization and storage, insulin sensitivity, and/or lipid metabolism. Proposals should specifically seek to advance our understanding of how metabolic dysregulation in individuals affects cancer risk and identify mechanisms that will enhance (i) cancer risk prediction, (ii) screening for high-risk individuals in clinical settings, and (iii) identification of potential targets for preventive and therapeutic interventions. This FOA is published in parallel with RFA-CA-21-022 Coordinating Center for the Metabolic Dysregulation and Cancer Risk Program: a Transdisciplinary Approach to Obesity-associated Research (U24 Clinical Trial Not Allowed). The individual research grants and the Coordinating Center funded under these FOAs together will constitute the Metabolic Dysregulation and Cancer Risk Program.
Funding Opportunity RFA-CA-21-022 from the NIH Guide for Grants and Contracts. The Metabolic Dysregulation and Cancer Risk Program is focused on metabolic dysregulation as the key process linking obesity with cancer risk. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support a Coordinating Center to facilitate coordination across multiple individual research project grants. The overarching goal of the Metabolic Dysregulation and Cancer Risk Program is to enhance our knowledge of the dynamics, and underlying mechanisms, that link obesity, metabolic dysregulation, and increased cancer risk. The Coordinating Center will have several responsibilities, including, but not limited to, provide administrative support to the Metabolic Dysregulation and Cancer Risk Program, facilitate and participating in collaborative research, create standard operating procedures and best practices to identify common measures/targets, collect core common data elements and biological samples (when appropriate), facilitate communication across researchers, provide meeting support, coordinating reviews of applications and distribution of research funds, create and maintain the Program website, and facilitate deposition of data to NIH repositories (when appropriate). This FOA is published in parallel with RFA-CA-21-021 Research Project Grants for the Metabolic Dysregulation and Cancer Risk Program: a Transdisciplinary Approach to Obesity-associated Research (U01 Clinical Trial Optional). The Coordinating Center and the individual research grants funded under these FOAs together will constitute the Metabolic Dysregulation and Cancer Risk Program.
Funding Opportunity RFA-AG-22-027 from the NIH Guide for Grants and Contracts. The goal of the GEMSSTAR program is to provide support for early-career physician-scientists trained in medical or surgical specialties or early-career dentist-scientists to launch careers as future leaders in aging- or geriatric-focused research. To achieve this goal, the GEMSSTAR Funding Opportunity Announcement (FOA) provides small grants to conduct transdisciplinary aging research that will yield pilot data and experience for subsequent aging research projects.
Notice NOT-GM-21-053 from the NIH Guide for Grants and Contracts
Notice NOT-HD-21-037 from the NIH Guide for Grants and Contracts
Notice NOT-DE-21-009 from the NIH Guide for Grants and Contracts
Notice NOT-HD-21-029 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-131 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-069 from the NIH Guide for Grants and Contracts